Ms. Amy T Buckner, MCD CCC A Audiologist Medicare: Medicare Enrolled Practice Location: 5204 W Redbud St, Rogers, AR 72758 Phone: 479-636-0110 Fax: 479-631-0491 |
Angela Kay Coleman, CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5204 W Redbud St, Rogers, AR 72758 Phone: 479-636-0110 Fax: 479-631-0491 |
Janean D Woods, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5204 W Redbud St, Rogers, AR 72758 Phone: 479-636-0110 Fax: 479-636-0491 |
Mrs. Lori E Rogers, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5204 W Redbud St, Rogers, AR 72758 Phone: 479-636-0110 Fax: 479-631-0491 |
Community Clinic Rogers Audiology Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1233 W Poplar St, Rogers, AR 72756 Phone: 479-751-7417 Fax: 479-751-4898 |
Mrs. Lara Jenkins Shepherd, CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5204 W Redbud St, Rogers, AR 72758 Phone: 479-636-0110 Fax: 479-631-0491 |
News Archive
Most attempts to develop imaging agents that can better distinguish tumors from healthy tissue focus on finding molecules that are more abundant on malignant cells than on normal cells and using those as cellular targets.
According to a new study published in the latest issue of The Lancet, this week, more people across the globe are dying of sepsis than earlier believed. A team from the University of Pittsburgh and University of Washington schools of medicine led the research along with their colleagues from different disciplines.
Early research indicates that the use of tumor-treating fields, a type of electromagnetic field therapy, along with chemotherapy in patients with a brain tumor who had completed standard chemoradiation resulted in prolonged progression-free and overall survival, according to a study in the December 15 issue of JAMA.
Mayo Clinic researchers studying patients in the emergency department with acute chest pain report in the current issue of Mayo Clinic Proceedings that exercise treadmill testing (ETT) was often sufficient for evaluation.
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
› Verified 2 days ago